Biotech IPOs surge sixfold to $3.72 Billion in Q1 2024, highest in over a year

New Delhi: Biotech initial public offerings (IPOs) experienced a dramatic resurgence in the first quarter (Q1) of 2024, with eight IPOs raising a total of $3.72 billion. This figure represents a sixfold increase from the $620 million raised in the previous quarter (Q4 2023) and marks the highest quarterly biotech IPO value in over a year.

The significant rise follows a two-year decline in biotech IPO values, indicating a strong return of investor confidence, according to GlobalData.

The surge in biotech IPOs in Q1 2024 comes after a notable downturn in previous years, with IPO raising dropping from $30.8 billion in 2020 to $5.9 billion in 2022 and $4.4 billion in 2023, according to GlobalData’s Pharmaceutical Intelligence Center This resurgence suggests a pent-up demand and a potential shift in market dynamics.

Ophelia Chan, Business Fundamentals Senior Analyst at GlobalData, comments: “High interest rates during 2022 and 2023 led investors to prioritize the existing portfolios over new opportunities, causing many biotechs to delay their IPOs until market conditions improved.”

The first quarter of 2024 set a robust pace for the year, with CG Oncology leading as the largest biotech IPO of the period, raising $437 million for its oncolytic virus therapy, CG-0070. Chan noted, “Despite a decline in IPOs in Q2 2024, companies with strong clinical data that previously struggled to secure funding may now see early 2024 successes as an opportunity to pursue public offerings.”

In the first half of 2024, six IPOs each raised over $100 million, collectively totaling nearly $5 billion—more than double the $2.2 billion raised by five high-value IPOs in H1 2023. This increase, coupled with additional venture funding, has revitalized investor enthusiasm. Biotech companies in Switzerland, the US, and India led the IPO raises, securing $2.5 billion, $1.5 billion, and $273 million, respectively.

The UK’s Financial Conduct Authority has recently updated its listing rules for the London Stock Exchange to facilitate public offerings and enhance London’s status as a major financial hub post-Brexit. The new regulations aim to boost Britain’s capital markets, attract more investment, and strengthen London’s competitive edge against financial centers like New York and the European Union.

Chan concluded: “The growth in completed IPOs in the first half of 2024 marks a positive shift following a period of downturn. This reflects renewed investor optimism to create new opportunities for companies with strong clinical data. The success of IPOs in the first quarter may prompt more biotechs to go public in the latter half of the year, although investors remain cautious as market conditions stabilize.”